Hypophosphatemia: an evidence-based problem-solving approach to clinical cases

Area of Science:

• Nephrology
• Endocrinology
• Biochemistry

Background:

• Hypophosphatemia is defined as serum phosphate < 2.5 mg/dL, resulting from various causes including inadequate intake, absorption issues, or renal phosphate wasting.
• Renal phosphate wasting, a key cause, can be genetic (e.g., X-linked hypophosphatemic rickets) or acquired (e.g., vitamin D deficiency, hyperparathyroidism, Fanconi syndrome).
• While often asymptomatic, severe hypophosphatemia can lead to muscle weakness, cardiac dysfunction, and altered mental status.

Purpose of the Study:

• To outline the diagnostic approach to hypophosphatemia, focusing on identifying renal phosphate wasting.
• To categorize renal phosphate wasting based on serum calcium levels.
• To describe current treatment strategies for hypophosphatemia.

Main Methods:

• Diagnosis begins with measuring fractional phosphate excretion; >15% confirms renal phosphate wasting.
• Classification of renal phosphate wasting into three types based on serum calcium: primary hyperparathyroidism (high Ca), secondary hyperparathyroidism (low Ca), and primary renal phosphate wasting (normal Ca).

Main Results:

• Fractional phosphate excretion >15% in hypophosphatemic patients confirms renal phosphate wasting.
• Renal phosphate wasting is categorized into three types based on serum calcium levels.
• Treatment indications include symptomatic patients or those with chronic phosphate wasting.

Conclusions:

• Oral phosphate and calcitriol are primary treatments for symptomatic hypophosphatemia or chronic renal phosphate wasting.
• Parenteral phosphate is reserved for life-threatening hypophosphatemia (serum phosphate < 2.0 mg/dL).
• Intravenous phosphate administration protocols are established for severe cases.